Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands

OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness of ravulizumab compared with eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) in the Netherlands. METHODS: A cost-effectiveness analysis was conducted based on a Markov cohort model...

Descripción completa

Detalles Bibliográficos
Autores principales: Quist, S. W., Postma, A. J., Myrén, K. J., de Jong, L. A., Postma, M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550878/
https://www.ncbi.nlm.nih.gov/pubmed/36633725
http://dx.doi.org/10.1007/s10198-022-01556-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550878/
https://www.ncbi.nlm.nih.gov/pubmed/36633725
http://dx.doi.org/10.1007/s10198-022-01556-5

Ejemplares similares